Arca
Skip to content

Adenocarcinoma

Drug research and approvals for adenocarcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 2,163 studies of adenocarcinoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 73 drug trials for it since 2013, FDA has 17 approved and 19 open orphan designations naming it, and the EU has 4 authorised medicines for it.

  • Recruiting worldwide: 2,163
  • Trials authorized in Canada: 73
  • FDA orphan approvals: 17
  • EU medicines: 4

Recruiting Now

Newest start dates first, of 2,163 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 73; search them all in Canada trials
Sep 3, 2026A phase 3, randomized, open-label study of zoldonrasib (rmc-9805) plus daraxonrasib (rmc-6236) versus gemcitabine and nab-paclitaxel as first-line treatment in…DARAXONRASIB (RMC-6236) / ZOLDONRASIB (RMC-9805)Revolution MedicinesPending
Aug 19, 2026A phase Ib, multicenter, randomized study evaluating the safety and activity of gdc-7035 with anti-cancer therapies as first-line treatment in patients with…GDC-7035 (RO7782493) / PANITUMUMAB / OXALIPLATIN / IRINOTECAN / GEMCITABINE /…RochePending
Jul 20, 2026A phase 2, open-label study of vs-7375, an oral kras g12d (on/off) inhibitor, as monotherapy and with cetuximab, in patients with metastatic kras g12d-mutated…VS-7375 (GFH375) / ERBITUX (CETUXIMAB) / VECTIBIX (PANITUMUMAB)VERASTEM ONCOLOGYOngoing
Jun 5, 2026A phase 3, randomized, double-blind, placebo-controlled study of investigator choice of chemotherapy (modified folfirinox or gemcitabine plus nabpaclitaxel)…ZOLDONRASIB (RMC-9805) / OXALIPLATIN / 5-FLUOROURACIL / FOLINIC ACID /…Revolution MedicinesPending
May 22, 2026A multicenter, first-in-human, dose escalation and optimization phase I/iia study to investigate safety, tolerability, pharmacokinetics, and efficacy of the…TUB-040TUBULIS GMBHPending
May 19, 2026Restage (repurposing statins to improve outcomes in gastroesophageal cancer) trial: a phase II randomized open-label trial of perioperative simvastatin plus…SIMVASTATINRESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTREPending
May 12, 2026A randomized, double-blind, phase 3 study of chemotherapy with or without incb161734 in previously untreated, kras g12d–mutated metastatic pancreatic ductal…INCB161734 / NAB-PACLITAXEL / GEMCITABINE / 5-FLUOROURACIL / IRINOTECAN /…Incyte CorporationOngoing
May 6, 2026Phase 2/3 open label randomized study of telisotuzumab adizutecan in combination with folfox compared to standard of care in subjects with first- line…ABBV-400 (TELISOTUZUMAB ADIZUTECAN) / FLUOROURACIL / FOLINIC ACID / OXALIPLATIN…AbbViePending
Apr 29, 2026Rasolute 303: a phase 3 global, multicenter, open-label, randomized, 3-arm study of daraxonrasib monotherapy or daraxonrasib plus gemcitabine and nabpaclitaxel…DARAXONRASIB (RMC-6236) / GEMCITABINE / NAB-PACLITAXELRevolution MedicinesOngoing
Mar 12, 2026A phase 2/3 interventional study of pf-08634404 in combination with chemotherapy in treatment-naive participants with locally advanced or metastatic gastric,…PF-08634404 / FLUOROURACIL / CALCIUM FOLINATE / OXALIPLATIN / CAPECITABINE /…PfizerOngoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 36
Aug 26, 2026Rasonquetreatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not…Revolution Medicines, Inc.Approved
Dec 4, 2024Bizengritreatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with…Partner Therapeutics, Inc.Approved
Feb 13, 2024Onivydein combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of adult patients with metastatic pancreatic…Ipsen Biopharmaceuticals, Inc.Approved
Nov 16, 2023Keytrudain combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced…MSD International Business GmbHApproved
Nov 15, 2023Augtyrotreatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)Bristol Myers Squibb CompanyApproved
May 5, 2021Keytrudain combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with…MSD International Business GmbHApproved
Jan 15, 2021Enhertutreatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who…Daiichi Sankyo, Inc.Approved
Dec 27, 2019LynparzaLynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic…AstraZeneca Pharmaceuticals LPApproved
Feb 22, 2019LONSURFLONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously…Taiho Oncology, Inc.Approved
Sep 22, 2017KeytrudaKEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction…MSD International Business GmbHApproved
Oct 22, 2015irinotecan liposome injectionFor use in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas that…Ipsen Biopharmaceuticals, Inc.Approved
Nov 5, 2014CYRAMZATreatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after…Eli Lilly and CompanyApproved
Apr 21, 2014CYRAMZACYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction…Eli Lilly and CompanyApproved
Sep 6, 2013AbraxaneTreatment of metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.Abraxis BioScience, LLCApproved
Apr 29, 2011FusilevFor use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancerAcrotech Biopharma LLCApproved

Medicines Authorised in the EU

Newest first
Nov 10, 2017TookadpadeliporfinSTEBA Biotech S.AEMA ↗
Oct 14, 2016Onivyde pegylated liposomal (previously Onivyde)irinotecan hydrochloride trihydrate · orphanLes Laboratoires ServierEMA ↗
Dec 19, 2014CyramzaramucirumabEli Lilly Nederland B.V.EMA ↗
Nov 21, 2014VargatefnintedanibBoehringer Ingelheim International GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.